novartis - dofaq.co
Novartis pays PeptiDream $180M as radiopharma big bang continues
Fierce Biotech - 30 Apr 2024
Novartis pays PeptiDream $180M as radiopharma big bang continues ...
Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership
BioSpace - 30 Apr 2024
Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership ...
PeptiDream Expands Peptide Discovery Collaboration With Novartis
Contract Pharma - 30 Apr 2024
PeptiDream Expands Peptide Discovery Collaboration With Novartis ...
Stock Watch: Novartis And The Changing Face Of Big Pharma
Scrip - 30 Apr 2024
Stock Watch: Novartis And The Changing Face Of Big Pharma ...
Morphosys says takeover by Novartis on course after report of drug safety concern
Reuters - 29 Apr 2024
Morphosys says takeover by Novartis on course after report of drug safety concern ...
New, serious safety risk related to MorphoSys' cancer drug complicates, potentially threatens, Novartis acquisition
STAT - 28 Apr 2024
New, serious safety risk related to MorphoSys' cancer drug complicates, potentially threatens, Novartis acquisition ...
Research and development
Novartis - 08 Feb 2024
Research and development ...
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis
Business Wire - 30 Apr 2024
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis ...
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Fierce Pharma - 26 Apr 2024
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia ...
NICE recommends Novartis precision brain cancer treatment
European Pharmaceutical Review - 24 Apr 2024
NICE recommends Novartis precision brain cancer treatment ...
Drugmaker Novartis climbs after guidance rise on sales of blockbuster drugs
CNBC - 23 Apr 2024
Drugmaker Novartis climbs after guidance rise on sales of blockbuster drugs ...
Novartis reports 25% increase in net income in Q1 2024
Pharmaceutical Technology - 24 Apr 2024
Novartis reports 25% increase in net income in Q1 2024 ...
Alexion and Novartis/Genentech start UPC's first ever biosimilar disputes
IAM - 24 Apr 2024
Alexion and Novartis/Genentech start UPC's first ever biosimilar disputes ...
From black holes to AI driven drug discovery – collaboration wins the day
Novartis - 29 Apr 2024
From black holes to AI driven drug discovery – collaboration wins the day ...
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT
BioSpace - 29 Apr 2024
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT ...
Novartis nominates ex-BMS chief Giovanni Caforio as its next chair
Fierce Pharma - 23 Apr 2024
Novartis nominates ex-BMS chief Giovanni Caforio as its next chair ...
Novartis in Society Integrated Report
Novartis - 31 Jan 2024
Novartis in Society Integrated Report ...
Novartis 'actively' reviewing relationships with Chinese contractors amid US biosecurity crackdown: CFO
Fierce Pharma - 23 Apr 2024
Novartis 'actively' reviewing relationships with Chinese contractors amid US biosecurity crackdown: CFO ...
Novartis dials up 2024 sales outlook, preps for key expansions of 3 cancer drugs
Fierce Pharma - 23 Apr 2024
Novartis dials up 2024 sales outlook, preps for key expansions of 3 cancer drugs ...